← BeOne Medicines Ltd.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $1.1m |
$238.4m
+22179.16%
|
$198.2m
-16.85%
|
$428.2m
+116.03%
|
$308.9m
-27.87%
|
$1.2b
+280.83%
|
$1.4b
+20.37%
|
$2.5b
+73.65%
|
$3.8b
+54.96%
|
$5.3b
+40.23%
|
$6.1b
+14.71%
|
|
| Cost of Revenue | $0 | $5.0m |
$28.7m
+477.10%
|
$71.2m
+148.01%
|
$70.7m
-0.75%
|
$164.9m
+133.39%
|
$286.5m
+73.72%
|
$379.9m
+32.62%
|
$594.1m
+56.37%
|
$668.5m
+12.53%
|
$680.7m
+1.82%
|
|
| Cost of sales - product | $0 | ($5.0m) |
($28.7m)
-477.10%
|
($71.2m)
-148.01%
|
$70.7m
+199.25%
|
$164.9m
+133.39%
|
$286.5m
+73.72%
|
$379.9m
+32.62%
|
$594.1m
+56.37%
|
$668.5m
+12.53%
|
— | |
| Gross Profit (derived) | $1.1m |
$233.4m
+21714.30%
|
$169.5m
-27.38%
|
$357.0m
+110.61%
|
$238.2m
-33.28%
|
$1.0b
+324.56%
|
$1.1b
+11.67%
|
$2.1b
+84.06%
|
$3.2b
+54.71%
|
$4.7b
+45.34%
|
$5.4b
+16.55%
|
|
| Interest Income (Expense), Net | $383k |
($4.1m)
-1172.58%
|
$13.9m
+439.51%
|
$9.1m
-34.53%
|
$2.0m
-78.12%
|
($15.8m)
-888.64%
|
$52.5m
+433.06%
|
$74.0m
+41.02%
|
— | — | $101.7m | |
| Research and Development Expense | $98.0m | $269.0m | $679.0m | $927.3m | $1.3b | $1.5b | $1.6b | $1.8b | $2.0b | $2.1b | $2.3b | |
| Selling, General and Administrative Expense | — | $62.6m | $195.4m | $388.2m | $600.2m | $990.1m | $1.3b | $1.5b | $1.8b | $2.1b | $2.2b | |
| Selling, general and administrative | ($20.1m) | ($62.6m) | ($195.4m) | ($388.2m) | $600.2m | $990.1m | $1.3b | $1.5b | $1.8b | $2.1b | $2.2b | |
| Amortization of Intangible Assets | — | $250k | $894k | $1.3m | $846k | $1.7m | $4.0m | $7.2m | $4.8m | $10.1m | — | |
| Operating expenses: | ||||||||||||
| Total operating expenses | ($118.1m) | ($336.8m) | ($904.0m) | ($1.4b) | $2.0b | $2.6b | $3.2b | $3.3b | $3.8b | $4.2b | $4.5b | |
| Operating Income (Loss) | ($117.1m) |
($98.5m)
+15.89%
|
($705.8m)
-616.83%
|
($959.9m)
-36.01%
|
($1.7b)
-72.69%
|
($1.4b)
+13.21%
|
($1.8b)
-24.39%
|
($1.2b)
+32.52%
|
($568.2m)
+52.95%
|
$447.1m
+178.69%
|
$923.1m
+106.45%
|
|
| Interest Expense, Debt | — | — | — | — | $18.3m | $29.3m | $21.7m | $20.8m | $46.9m | $50.0m | $115.9m | |
| Interest income | — | — | — | — | — | — | — | $78.4m | $69.6m | $70.5m | $101.7m | |
| Equity Securities, FV-NI, Realized Gain (Loss) | — | — | — | — | — | — | — | — | — | ($16.6m) | — | |
| Gain (Loss) on Investments | — | — | — | — | — | — | — | — | — | ($596k) | — | |
| Gain (Loss) Related to Litigation Settlement | — | — | — | — | — | — | — | $362.9m | $0 | $0 | — | |
| Other Nonoperating Income (Expense) | $443k | $11.5m | $2.0m | $7.2m | $37.5m | $15.9m | ($223.9m) | $307.9m | ($12.6m) | ($42.6m) | — | |
| Income (Loss) from Equity Method Investments | — | — | — | — | $11.8m | $7.6m | ($22.0m) | ($16.2m) | — | — | — | |
| Interest Expense (non-operating) | — | — | — | — | — | — | — | $4.4m | $21.8m | $58.2m | $115.9m | |
| Interest Income (Expense), Nonoperating, Net | — | — | — | — | — | — | — | — | $47.8m | — | $101.7m | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | ($59.6m) | ($130.6m) | ($232.0m) | — | — | — | — | — | — | $868.1m | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | ($119.2m) | — | — | — | — | — | ($2.0b) | ($825.8m) | ($533.0m) | $416.9m | $868.1m | |
| Current Income Tax Expense (Benefit) | $822k | $8.2m | $6.5m | $16.4m | $10.5m | $16.0m | $39.3m | $55.2m | $85.8m | $120.5m | $212.4m | |
| Income Tax Expense (Benefit) | $54k | $2.2m | ($15.8m) | $7.0m | ($17.7m) | ($25.2m) | $42.8m | $55.9m | $111.8m | $129.9m | $212.4m | |
| Net Income (Loss) Attributable to Parent | ($119.2m) |
($93.1m)
+21.90%
|
($673.8m)
-623.67%
|
($948.6m)
-40.79%
|
($1.6b)
-68.34%
|
($1.4b)
+11.49%
|
($2.0b)
-41.78%
|
($881.7m)
+56.00%
|
($644.8m)
+26.87%
|
$286.9m
+144.50%
|
$655.7m
+128.52%
|
|
| Net Income (Loss) Attributable to Noncontrolling Interest | — | ($194k) | ($264k) | ($1.9m) | ($3.6m) | $0 | $0 | — | — | — | $655.7m | |
| Earnings Per Share, Basic | — | — | — | ($15.80) | ($19.13) | ($1.17) | ($1.49) | ($0.65) | ($0.47) | $0.20 | $5.85 | |
| Earnings Per Share, Diluted | ($0.30) | ($2.23) | ($12.15) | ($15.80) | ($19.13) | ($1.17) | ($1.49) | ($0.65) | ($0.47) | $0.19 | $5.59 | |
| Weighted-average ADSs outstanding, basic (in shares) | — | — | — | 60.1m | 83.5m | 92.8m | 103.1m | 104.4m | 105.3m | 109.1m | — | |
| Weighted-average ADSs outstanding, diluted (in shares) | — | — | — | 60.1m | 83.5m | 92.8m | 103.1m | 104.4m | 105.3m | 113.4m | — | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | — | 780.7m | 1.1b | 1.2b | 1.3b | 1.4b | 1.4b | 1.4b | 110.9m | |
| Weighted-average shares outstanding—basic (in shares) | — | — | — | 780.7m | 1.1b | 1.2b | 1.3b | 1.4b | 1.4b | 1.4b | — | |
| Weighted-average shares outstanding— diluted (in shares) | — | — | — | 780.7m | 1.1b | 1.2b | 1.3b | 1.4b | 1.4b | 1.5b | — | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | 780.7m | 1.1b | 1.2b | 1.3b | 1.4b | 1.4b | 1.5b | 115.4m | |
| Additional Financial Items | ||||||||||||
| Costs and Expenses | $118.1m | $336.8m | $904.0m | $1.4b | $2.0b | $2.6b | $3.2b | $3.3b | $3.8b | $4.2b | — | |
| Income (loss) from operations | ($117.1m) |
($98.5m)
+15.89%
|
($705.8m)
-616.83%
|
($959.9m)
-36.01%
|
($1.7b)
-72.69%
|
($1.4b)
+13.21%
|
($1.8b)
-24.39%
|
($1.2b)
+32.52%
|
($568.2m)
+52.95%
|
$447.1m
+178.69%
|
$923.1m
+106.45%
|
|
| Other (expense) income, net | $443k | $11.5m | $2.0m | $7.2m | $37.5m | $15.9m | ($223.9m) | $307.9m | ($12.6m) | ($42.6m) | — | |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | ($119.2m) | — | — | — | — | — | — | — | — | — | — |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.